<DOC>
	<DOCNO>NCT02471105</DOCNO>
	<brief_summary>This cross-over study investigate efficacy safety BIMMD TUDPF clinical setting .</brief_summary>
	<brief_title>Investigation IOP Tolerability Bimatoprost 0.01 % Tafluprost Unit Dose Preservative Free 15 Microgram/ml</brief_title>
	<detailed_description>- A prospective , randomize , investigator-masked , crossover comparison ; - Ocular hypertension glaucoma ( XFG POAG ) patient consent participate enrol study - Patients schedule screen visit IOP assessment ( IOP measurements 08:30 , 12:30 16:30 ( ±1 hour ) . - Patients therapy screen visit consent participate undergo washout period 4 week ( depend therapy ) baseline visit ; - Patient washout period give brinzolamide ( Azopt ) need , Azopt discontinue 5 day baseline visit ; - After screen visit ( wash-outperiod treat patient ) patient schedule undergo baseline visit IOP assessment ( IOP measurements 08:30 , 12:30 16:30 ( ± 1 hour minimum 3 hour reading ) randomize Period 1 receive either BIMMD drop evening ( 20:30 ) TUDPF drop evening ( 20:30 ) 3 month - After 3 month , patient switch Period 2 , opposite treatment ( e.g . switch either BIMMD TUDPF ) dose evening ; - After another 3 month undergo final evaluation IOP level tolerability ; - Intermediate safety visit may schedule discretion investigator .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>A patient suffer ocular hypertension , XFG POAG need treatment eye Patient least 18 year Patient able willing participate study whole duration follow willing sign consent form . Unwilling sign inform consent ; Younger 18 year old ; Ocular condition safety concern interfere study result ; Visual field defect MD value 15dB either eye Humphrey ( equivalent Octopus ) and/or threaten fixation Contact lens wearer ; Closed/barely open anterior chamber angle history acute angle closure either eye assess gonioscopy ; Ocular surgery ( glaucoma surgery ) argon laser trabeculoplasty within past three month either eye ; Glaucoma surgery within past 6 month either eye ; Ocular inflammation/infection occur within three month prior pretrial visit either eye ; Concomitant topical ocular medication interfere study medication either eye ; Known hypersensitivity component trial drug solution ; Other abnormal condition symptom prevent patient enter trial , accord Investigator 's judgement ; Refractive surgery patient time ; Women pregnant , childbearing potential use adequate contraception nursing ; Inability adhere treatment/visit plan ; Have participate Interventional clinical trial ( i.e. , require inform consent ) involve investigational drug within one month prior pretrial visit . History COPD , asthma heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>